Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026)

Vanda Pharmaceuticals has disclosed Capital Expenditures across 16 years of filings, most recently posting $221000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $221000.0, down 49.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $783000.0 (down 14.8% YoY), and the FY2025 annual result was $998000.0, up 103.67% from the prior year.
• Capital Expenditures came in at $221000.0 for Q1 2026 at Vanda Pharmaceuticals, up from $102000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $436000.0 in Q1 2025 to a low of $7000.0 in Q1 2024.
• The 5-year median for Capital Expenditures is $161000.0 (2024), against an average of $163000.0.
• Across the five-year window, Capital Expenditures slumped 86.27% in 2024 and soared 6128.57% in 2025, its largest moves.
• Vanda Pharmaceuticals' Capital Expenditures stood at $263000.0 in 2022, then decreased by 3.8% to $253000.0 in 2023, then retreated by 15.42% to $214000.0 in 2024, then plunged by 52.34% to $102000.0 in 2025, then jumped by 116.67% to $221000.0 in 2026.
• The last three Capital Expenditures figures came in at $221000.0 (Q1 2026), $102000.0 (Q4 2025), and $161000.0 (Q3 2025), per Business Quant data.